類克生物相似藥市場：依產品類型、最終用戶、適應症和地區Remicade

Remicade Biosimilars Market, By Product Type, By End User, By Indication, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計， Remicade生物相似藥市場在2026年的價值為43.2億美元，預計到2033年將達到106.1億美元。預計從2026年到2033年，其複合年成長率將達到13.7%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	43.2億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	13.70%	2033年市場規模預測：	106.1億美元

全球Remicade biosimilar市場涵蓋Infliximab、Adalimumab、Etanercept及類似產品。這些藥物廣泛應用於醫院、專科診所、零售藥局及其他醫療機構，並被各類終端使用者所接受。隨著各機構日益重視療效、效率和成本效益，這些藥物在這些領域的應用也持續穩定成長。

市場動態：

來自主要終端用戶產業的需求不斷成長、對更高效率和可靠性的需求以及持續的產品創新，預計將是推動全球Remicade biosimilar市場成長的主要因素。醫院和專科診所的廣泛應用進一步加速了這一成長勢頭。

例如，市場參與者正在實施專為醫院應用場景設計的先進解決方案。此外，預計持續的技術進步和策略投資將在整個預測期內為市場參與者創造新的成長機會。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，介紹了全球Remicade biosimilar市場主要參與者的概況。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「全球Remicade相似藥市場」報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
相關人員可以透過分析全球Remicade生物相似藥市場時所使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
中東和非洲
巴林
科威特
阿曼
卡達
沙烏地阿拉伯
UAE
以色列
南非
北非
中非
其他中東國家

第1章競爭情勢

Pfizer Inc.
Samsung Bioepis
Celltrion, Inc.
Sandoz（a Novartis division）
Biocon Ltd.
Amgen Inc.
Mylan NV
Dr. Reddy's Laboratories
Zydus Cadila
Intas Pharmaceuticals
Lupin Ltd.
Teva Pharmaceuticals

第2章

調查方法
關於本公司

簡介目錄

Product Code: CMI1769

Remicade Biosimilars Market is estimated to be valued at USD 4.32 billion in 2026 and is expected to reach USD 10.61 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4.32 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.70%	2033 Value Projection:	USD 10.61 billion

The global remicade biosimilars market includes offerings that span Infliximab, Adalimumab, and Etanercept, and similar product type categories. These are applied across Hospitals, Specialty Clinics, and Retail Pharmacies and adopted by diverse end users. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.

Market Dynamics:

Increasing demand from major end-use sectors, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global remicade biosimilars market. Broader adoption across Hospitals, and Specialty Clinics is reinforcing this momentum.

For instance, market players are introducing advanced solutions designed for Hospitals use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global remicade biosimilars market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Samsung Bioepis, Celltrion, Inc., Sandoz (a Novartis division), Biocon Ltd., Amgen Inc., Mylan N.V., Dr. Reddys Laboratories, Zydus Cadila, Intas Pharmaceuticals, Lupin Ltd., and Teva Pharmaceuticals, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global remicade biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global remicade biosimilars market.

Detailed Segmentation:

Global Remicade Biosimilars Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
Infliximab
Adalimumab
Etanercept
Others
Global Remicade Biosimilars Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Specialty Clinics
Retail Pharmacies
Others
Global Remicade Biosimilars Market, By Indication (Revenue, USD Bn, 2021 - 2033)
Rheumatoid Arthritis
Crohns Disease
Psoriasis
Ulcerative Colitis
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Samsung Bioepis
Celltrion, Inc.
Sandoz (a Novartis division)
Biocon Ltd.
Amgen Inc.
Mylan N.V.
Dr. Reddys Laboratories
Zydus Cadila
Intas Pharmaceuticals
Lupin Ltd.
Teva Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By End User
- Market Snapshot, By Indication
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Remicade Biosimilars Market By Product Type, 2026-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Infliximab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Adalimumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Etanercept
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Remicade Biosimilars Market By End User, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Remicade Biosimilars Market By Indication, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Crohn's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Remicade Biosimilars Market By Region, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
UAE
Israel
South Africa
North Africa
Central Africa
Rest of the Middle East

1. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Celltrion, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biocon Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Dr. Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intas Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies